GSK Buys Nuvalent for $10.6 Billion in Massive Cancer Drug Bet
The deal gives GSK two potential best-in-class lung cancer drugs and accelerates its oncology growth.
/ 2 items
The deal gives GSK two potential best-in-class lung cancer drugs and accelerates its oncology growth.
H.C. Wainwright, Stifel, and Cantor Fitzgerald issue Buy ratings on five biotech stocks including Syndax, Black Diamond, Revolution Medicines, Verastem, and Nuvalent, citing breakthrough cancer treatments.